Psyga

Name

Psyga

Legal name

Psyga Bio Ltd.

Website

https://cannasoul.co.il

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Psychedelic Therapeutics Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Psychedelic therapeutics
• Psilocybin drug discovery
• Clinical stage biotechnology
• GMP pharmaceutical manufacturing
• Natural product pharmaceuticals

Headquarters

HQ city

Caesarea

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Pharmaceutical Development and Licensing: As a drug discovery company developing psychedelic mushroom-derived therapeutics, Psyga's revenue model centers on developing pharmaceutical products through clinical trials with the goal of bringing clinical approved formulations to market. The company is in clinical development stage with seven Phase 2a trials pending enrollment.
2. Drug Development Services: Psyga Bio uses Cannasoul's proprietary analytical platform, data-driven approach, unique knowhow and clinical trial framework to support active compound identification and development from mushrooms cultivation and extraction for clinical approved formulations.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Psyga Bio is a clinical-stage drug discovery company developing therapeutics derived from psychedelic and functional mushrooms, primarily psilocybin and psilocin, for mental health, addiction and neurological indications. The company leverages a proprietary library of more than 180 mushroom strains, a GMP-ready manufacturing facility, and Cannasoul's analytical platform to advance seven approved Phase 2a human clinical trials toward eventual licensing or commercialization.

Product overview

Psyga Bio is a drug discovery company developing groundbreaking therapeutics derived from psychedelic and functional mushroom-derived compounds. Operating as a subsidiary of the Cannasoul Group, Psyga Bio leverages its parent company's proprietary analytical platform, data-driven approach, and clinical trial framework to advance its drug development pipeline. The company's core offerings include its drug discovery platform focused on psilocybin and psilocin-based therapeutics, supported by a proprietary library of over 180 unique mushroom strains. Psyga is currently advancing seven Phase 2a human clinical trials for mental health disorders, addiction treatment, and neurological conditions. The integrated platform combines genetic diversity capabilities, chemical analytics, compound isolation and synthesis, functional biological screening, and clinical trial execution.

Differentiator

Problem solved

Functional benefit

Products and services

• Psyga Bio Drug Discovery Platform

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• XTL Biopharmaceuticals Ltd.flagshipStrategic or Co-development Partner · 29 April 2026XTL Biopharmaceuticals has entered into a definitive share purchase agreement to acquire 100% of Psyga Bio Ltd. Psyga shareholders will receive ADSs representing 40% of XTL's share capital at closing, with no cash consideration. Additional milestone-based earnout provisions entitle Psyga shareholders to an additional 10% equity stake upon achievement of each of three specified milestones.
• Cannasoul AnalyticscoreStrategic or Co-development PartnerPsyga Bio operates in partnership with Cannasoul Analytics, leveraging their proprietary analytical platform, data-driven approach, unique knowhow and clinical trial framework. This partnership supports active compound identification and development from mushroom cultivation and extraction through to clinical approved formulations.
• Technion – Israel Institute of TechnologycoreStrategic or Co-development PartnerPsyga Bio is founded by Prof. Dedi Meiri from the Technion. The company conducts pre-clinical screening and biological screening of psilocybin extracts and novel molecules in collaboration with Prof. Meiri's lab at the Technion – Israel Institute of Technology.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cybin: Canadian psychedelic therapeutics company developing deuterated psilocybin and DMT-based therapies for mental health. Direct psilocybin peer with overlapping psychiatric indications, GMP manufacturing, and similar clinical-stage positioning to Psyga.
• Mind Medicine (MindMed): Clinical-stage psychedelic medicine biotech developing LSD and psilocybin-based therapies for anxiety, ADHD, and substance use disorders. Comparable to Psyga in the psychedelic drug discovery space targeting overlapping indications (mental health, addiction) with multiple Phase 2 programs.
• Compass Pathways: UK-based clinical-stage company developing psilocybin therapy for treatment-resistant depression. Directly comparable to Psyga as a psilocybin-focused drug discovery company advancing mental health indications through Phase 2/3 trials, with similar mechanism (serotonergic psychedelic) and target indications.
• Beckley Psytech: UK-based clinical-stage psychedelic medicine company developing psilocybin and other psychedelic compounds for neurological and psychiatric indications. Comparable in stage, indication overlap (mental health, neurology), and psilocybin-focused pipeline as Psyga.
• GH Research: Ireland-based clinical-stage company developing mebufotenin and other psychedelic compounds for treatment-resistant depression. Comparable as a small-cap psychedelic drug developer pursuing mental health indications with Phase 2a-stage assets similar to Psyga.
• Filament Health: Canadian clinical-stage company developing naturally-derived psilocybin drug candidates. Direct peer given shared focus on natural/botanical psilocybin extraction, formulation, and GMP manufacturing — closely mirrors Psyga's strain library and GMP positioning.

Emerging players

• Silo Pharma: Small clinical-stage psychedelic and CNS-focused biotech developing psilocybin-based therapies for mental health and pain. Comparable as an emerging psilocybin therapeutics developer targeting overlapping indications with Psyga, though at smaller scale.
• Field Trip Health: Canadian psychedelic therapy company that operated clinics and developed psilocybin-based treatments. Adjacent peer as a clinical-stage psilocybin developer in the same therapeutic space, though more weighted toward clinical delivery than drug discovery.

Others

• XTL Biopharmaceuticals: Public Israeli biopharmaceutical company that is currently acquiring Psyga Bio Ltd. for 40% of share capital plus earnouts. Relevant as acquirer and future parent rather than competitor; gives a sense of how Psyga's pipeline translates into a public-market biopharma context.

Broad incumbents

• Atai Life Sciences: Berlin-based platform psychedelic mental health company with broad pipeline across multiple compounds and indications including psilocybin, DMT, and ibogaine. Larger incumbent in the same space as Psyga, backing multiple psychedelic-focused subsidiaries — comparable as a broad psychedelic drug development platform rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/psygabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psyga